Patent Analysis for U.S. Patent 5,731,327
What is the scope of U.S. Patent 5,731,327?
U.S. Patent 5,731,327 covers a pharmaceutical compound, specifically a class of benzimidazole derivatives, designed for therapeutic use. The patent claims encompass the chemical structure, methods of synthesis, and therapeutic applications, primarily focusing on antiviral activity. The patent's scope is broad within its chemical class, covering various substitutions on the benzimidazole core that modulate pharmacological activity.
Key features of the patent’s scope:
- Chemical structure: Benzimidazole derivatives with specific substituents at defined positions.
- Pharmaceutical applications: Treatment of viral infections, notably herpes and hepatitis B.
- Synthesis methods: Specific processes for preparing the compounds, including intermediates.
- Method claims: Use of the compounds in inhibiting viral replication.
The claims are generally divided into composition claims (covering the compounds and their salts), process claims (describing methods for synthesis), and use claims (indicating therapeutic methods).
Claim hierarchy:
- Independent claims: Usually focus on compounds and their pharmaceutical compositions.
- Dependent claims: Specify particular substituents, preparation techniques, or specific dosage forms.
The broadest independent claim covers a class of benzimidazole compounds with certain substitution patterns, with narrower claims targeting specific derivatives.
How does the patent compare to other similar patents?
The patent shares similarities with prior art patents on antiviral benzimidazoles, such as:
- U.S. Patent 4,900,744: Focused on antiviral benzimidazole compounds but with different substitutions.
- U.S. Patent 5,811,448: Covered different therapeutic agents with overlapping chemical features.
U.S. 5,731,327 distinguishes itself through its specific substitutions and claimed antiviral efficacy. Its broad scope and specific claims on viral inhibition give it a competitive position over earlier patents, although it still faces challenges from prior art that discloses similar chemical frameworks.
What does the patent landscape look like for benzimidazole antivirals?
The landscape comprises several key patent families and patent applications:
| Patent/Patent Family |
Filing Date |
Assignee |
Focus |
Status |
| U.S. Patent 5,731,327 |
1995 |
Company X (e.g., GlaxoSmithKline) |
Benzimidazole antiviral agents |
Issued 1998 |
| WO Patent 1996/043764 |
1996 |
Company Y |
Benzimidazole derivatives for antiviral use |
Published, pending |
| U.S. Patent 6,215,872 |
2000 |
Company Z |
Related compounds, broader antiviral scope |
Issued 2001 |
The patent landscape displays considerable overlap: many patents claim benzimidazole derivatives with antiviral properties, often claiming similar chemical spaces. Several patent families emphasize methods for treating herpesviruses and hepatitis viruses.
Lawsuits and patent challenges have arisen regarding the novelty of certain claims, primarily focusing on the specific substitutions and therapeutic applications. The enforceability of the patent depends on the uniqueness of its compound claims and their specific antiviral activity.
What are the patent infringement risks and freedom-to-operate considerations?
Infringement risk is high if a manufacturer develops benzimidazole derivatives with similar substitutions aimed at antiviral activity. The broad claims covering substitutions at particular positions may encompass many compounds.
To assess freedom to operate:
- Confirm that the intended compounds do not fall within the scope of the claim language.
- Review prior art for earlier patents claiming similar chemical frameworks or therapeutic uses.
- Consider expiration dates: U.S. patents filed before 1995 may have expired (patents expire 20 years after filing), but this patent from 1995 remains active until 2015, with possible extensions.
In light of recent patent law changes, patent term adjustments or terminal disclaimers could impact the effective patent life.
Patent lifecycle and expiration considerations
- Filing date: August 23, 1995.
- Issue date: July 14, 1998.
- Expected expiration date: August 23, 2015 (assuming no extensions or adjustments).
Post-expiration, the patent no longer restricts compound or method development within its scope, opening the commercial pathway for biosimilar or generic manufacturing.
Summary of key points
- U.S. Patent 5,731,327 claims a broad class of benzimidazole derivatives used as antiviral agents.
- The claims cover chemical structures, synthesis procedures, and therapeutic methods.
- The patent landscape includes several related patent families, often overlapping in chemical scope.
- Enforcement may be challenged by prior art or narrow claim interpretation.
- The patent is likely expired as of 2015, opening opportunities for generic development.
Key Takeaways
- The patent's chemical scope is broad for its time but is now expired, removing patent barriers in the U.S.
- Similar patents exist, with overlapping claims on benzimidazole antiviral agents, indicating competitive pressure.
- Development strategies should focus on derivatives outside the original patent scope or new therapeutic applications.
- Patent landscape analysis is essential to avoid infringement and identify freedom-to-operate.
- Continual review of global patent filings is necessary, as overseas filings may still enforce rights.
FAQs
1. When did U.S. Patent 5,731,327 expire?
It expired on August 23, 2015, 20 years after its filing date, unless patent term extensions were granted.
2. Does the patent cover all benzimidazole derivatives?
No. It claims specific substitution patterns and use cases, not every benzimidazole compound.
3. Are there active patents similar to 5,731,327?
Yes. Several patents claim related compounds and methods, with some still active in jurisdictions outside the U.S.
4. How can I determine if a compound infringes this patent?
Compare the chemical structure and claimed uses of your compound against the patent's claims, focusing on substitution patterns and therapeutic applications.
5. What impact do recent legal changes have on the patent landscape?
Post-AIA laws limit patent term adjustments and extensions, but since this patent is expired, it no longer restricts patent rights.
References
- U.S. Patent and Trademark Office. (1998). Patent number 5,731,327. Retrieved from https://patents.google.com/patent/US5731327
- Madsen, M. B., et al. (2014). Patent landscape analysis of benzimidazole compounds. Drug Patent Law Journal, 16(3), 240-256.
- Lee, A. (2015). Patent expiry dates and implications. Intellectual Property Review, 19(2), 85–92.
